These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34467985)

  • 1. Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019.
    Noh JY; Kwak JE; Yang JS; Hwang SY; Yoon JG; Seong H; Hyun H; Lim CS; Yoon SY; Ryou J; Lee JY; Kim SS; Park SH; Cheong HJ; Kim WJ; Shin EC; Song JY
    J Infect Dis; 2021 Sep; 224(5):754-763. PubMed ID: 34467985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
    Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
    J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.
    Hyun H; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
    Front Immunol; 2024; 15():1385135. PubMed ID: 38756783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
    Khoshkam Z; Aftabi Y; Stenvinkel P; Paige Lawrence B; Rezaei MH; Ichihara G; Fereidouni S
    J Adv Res; 2021 Jul; 31():49-60. PubMed ID: 33520309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination.
    Almendro-Vázquez P; Laguna-Goya R; Ruiz-Ruigomez M; Utrero-Rico A; Lalueza A; Maestro de la Calle G; Delgado P; Perez-Ordoño L; Muro E; Vila J; Zamarron I; Moreno-Batanero M; Chivite-Lacaba M; Gil-Etayo FJ; Martín-Higuera C; Meléndez-Carmona MÁ; Lumbreras C; Arellano I; Alarcon B; Allende LM; Aguado JM; Paz-Artal E
    PLoS Pathog; 2021 Dec; 17(12):e1010211. PubMed ID: 34962970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer.
    Chen C; Zhou X; Gao X; Pan R; He Q; Guo X; Yu S; Wang N; Zhao Q; Wang M; Xu Y; Han X
    Int J Cancer; 2024 Oct; 155(8):1409-1421. PubMed ID: 38837354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
    Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
    Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.
    Wu J; Liang B; Chen C; Wang H; Fang Y; Shen S; Yang X; Wang B; Chen L; Chen Q; Wu Y; Liu J; Yang X; Li W; Zhu B; Zhou W; Wang H; Li S; Lu S; Liu D; Li H; Krawczyk A; Lu M; Yang D; Deng F; Dittmer U; Trilling M; Zheng X
    Nat Commun; 2021 Mar; 12(1):1813. PubMed ID: 33753738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults.
    Björkander S; Du L; Zuo F; Ekström S; Wang Y; Wan H; Sherina N; Schoutens L; Andréll J; Andersson N; Georgelis A; Bergström A; Marcotte H; Kull I; Hammarström L; Melén E; Pan-Hammarström Q;
    J Allergy Clin Immunol; 2022 Jan; 149(1):65-75.e8. PubMed ID: 34695490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Henss L; Scholz T; von Rhein C; Wieters I; Borgans F; Eberhardt FJ; Zacharowski K; Ciesek S; Rohde G; Vehreschild M; Stephan C; Wolf T; Hofmann-Winkler H; Scheiblauer H; Schnierle BS
    J Infect Dis; 2021 Jan; 223(1):56-61. PubMed ID: 33128369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
    Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
    Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Harrington P; Doores KJ; Radia D; O'Reilly A; Lam HPJ; Seow J; Graham C; Lechmere T; McLornan D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison C; de Lavallade H
    Br J Haematol; 2021 Sep; 194(6):999-1006. PubMed ID: 34085278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study.
    Kohler P; Jonsdottir HR; Risch L; Vernazza P; Ackermann-Gäumann R; Kahlert CR
    Sci Rep; 2021 Dec; 11(1):24198. PubMed ID: 34921220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.
    Tsang HW; Chua GT; To KKW; Wong JSC; Tu W; Kwok JSY; Wong WHS; Wang X; Zhang Y; Rosa Duque JS; Chan GCF; Chu WK; Pang CP; Tam PKH; Lau YL; Wong ICK; Leung WH; Yuen KY; Kwan MYW; Ip P
    Front Immunol; 2021; 12():797919. PubMed ID: 34975908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.
    von Metzler I; Campe J; Huenecke S; Raab MS; Goldschmidt H; Schubert R; Rabenau HF; Ciesek S; Serve H; Ullrich E
    J Mol Med (Berl); 2022 Mar; 100(3):463-470. PubMed ID: 34657968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association Between Antibody Responses and Prolonged Viable Severe Acute Respiratory Syndrome Coronavirus 2 Shedding in Immunocompromised Patients: A Prospective Cohort Study.
    Lim SY; Kim JW; Kim JY; Kang SW; Jang CY; Chang E; Yang JS; Kim KC; Jang HC; Kim DS; Shin Y; Lee JY; Kim SH
    J Infect Dis; 2024 Jun; 229(6):1722-1727. PubMed ID: 38114088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.